161 related articles for article (PubMed ID: 37072866)
1. "Major pathologic response" in lymph nodes: a modified nodal classification for non-small cell lung cancer patients treated with neoadjuvant immunochemotherapy.
Deng H; Xiong S; Zhong R; Zheng Y; Liang H; Cheng B; Li J; Li F; Chen Z; Wang H; He J; Liang W
Exp Hematol Oncol; 2023 Apr; 12(1):40. PubMed ID: 37072866
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy.
Pataer A; Weissferdt A; Vaporciyan AA; Correa AM; Sepesi B; Wistuba II; Heymach JV; Cascone T; Swisher SG
J Thorac Oncol; 2021 Aug; 16(8):1289-1297. PubMed ID: 33857666
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of neoadjuvant immunochemotherapy and survival surrogate analysis of neoadjuvant treatment in IB-IIIB lung squamous cell carcinoma.
Liu J; Zhu L; Tang M; Huang X; Gu C; He C; Lv X; Hu J
Sci Rep; 2024 Mar; 14(1):5523. PubMed ID: 38448498
[TBL] [Abstract][Full Text] [Related]
4. Major pathologic response assessment and clinical significance of metastatic lymph nodes after neoadjuvant therapy for non-small cell lung cancer.
Liu X; Sun W; Wu J; Feng Y; Mao L; Chen M; Yang X; Wang H; Chi K; Yang Y; Lin D
Mod Pathol; 2021 Nov; 34(11):1990-1998. PubMed ID: 34253867
[TBL] [Abstract][Full Text] [Related]
5. Pathological response and prognostic factors of neoadjuvant PD-1 blockade combined with chemotherapy in resectable oesophageal squamous cell carcinoma.
Wang H; Jiang Z; Wang Q; Wu T; Guo F; Xu Z; Yang W; Yang S; Feng S; Wang X; Chen S; Cheng C; Chen W
Eur J Cancer; 2023 Jun; 186():196-210. PubMed ID: 37045666
[TBL] [Abstract][Full Text] [Related]
6. Different pathologic responses to neoadjuvant anti-PD-1 in primary squamous lung cancer and regional lymph nodes.
Ling Y; Li N; Li L; Guo C; Wei J; Yuan P; Tan F; Tao X; Wang S; Wang Z; Wu N; Wang J; Ying J; Gao S; He J
NPJ Precis Oncol; 2020 Dec; 4(1):32. PubMed ID: 33299121
[TBL] [Abstract][Full Text] [Related]
7. Preoperative immunochemotherapy for locally advanced non-small cell lung cancer: an analysis of the clinical outcomes, optimal number of cycles, and peripheral immune markers.
Deng H; Liang H; Chen J; Wang W; Li J; Xiong S; Cheng B; Li C; Chen Z; Wang H; Zheng J; Guo Z; He J; Liang W
Transl Lung Cancer Res; 2022 Dec; 11(12):2364-2381. PubMed ID: 36636407
[TBL] [Abstract][Full Text] [Related]
8. Immune-related histologic phenotype in pretreatment tumour biopsy predicts the efficacy of neoadjuvant anti-PD-1 treatment in squamous lung cancer.
Yuan P; Guo C; Li L; Ling Y; Guo L; Ying J
BMC Med; 2022 Oct; 20(1):403. PubMed ID: 36280845
[TBL] [Abstract][Full Text] [Related]
9. Is major pathologic response sufficient to predict survival in resectable nonsmall-cell lung cancer patients receiving neoadjuvant chemotherapy?
Cai JS; Li S; Yan SM; Yang J; Yang MZ; Xie CL; Li JB; Feng YF; Yang HX; Hou X
Thorac Cancer; 2021 May; 12(9):1336-1346. PubMed ID: 33751832
[TBL] [Abstract][Full Text] [Related]
10. Tertiary lymphoid structures combined with biomarkers of inflammation are associated with the efficacy of neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: A retrospective study.
Xu F; Zhu H; Xiong D; Wang K; Dong Y; Li L; Yuan S
Thorac Cancer; 2024 Jan; 15(2):172-181. PubMed ID: 38057283
[TBL] [Abstract][Full Text] [Related]
11. Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis.
Zhai WY; Zhao ZR; Chen S; Yu H; Lin YB; Wang YZ; Long H
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36109085
[TBL] [Abstract][Full Text] [Related]
12. A prognostic score for non-small cell lung cancer resected after neoadjuvant therapy in comparison with the tumor-node-metastases classification and major pathological response.
Zens P; Bello C; Scherz A; Koenigsdorf J; Pöllinger A; Schmid RA; Ochsenbein A; Neppl C; Langer R; Berezowska S
Mod Pathol; 2021 Jul; 34(7):1333-1344. PubMed ID: 33714982
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients' overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study.
Dai F; Wu X; Wang X; Li K; Wang Y; Shen C; Zhou J; Niu H; Deng B; Tan Q; Wang R; Guo W
Front Oncol; 2022; 12():1022123. PubMed ID: 36353552
[TBL] [Abstract][Full Text] [Related]
14. Pathologic Processing of Lung Cancer Resection Specimens After Neoadjuvant Therapy.
Weissferdt A; Leung CH; Lin H; Sepesi B; William WN; Swisher SG; Cascone T; Lee JJ; Pataer A
Mod Pathol; 2024 Jan; 37(1):100353. PubMed ID: 37844869
[TBL] [Abstract][Full Text] [Related]
15. "Percentage" and "size" of residual viable tumor in lymph node, the performance in estimating pathologic response of lymph node in non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy.
Sun W; Qu L; Wu J; Liu X; Wang C; Jiang Y; Liu Y; Chen M; Wang X; Lin D
Hum Pathol; 2024 May; 149():1-9. PubMed ID: 38782102
[TBL] [Abstract][Full Text] [Related]
16. Impact of treatment interval between neoadjuvant immunochemotherapy and surgery in lung squamous cell carcinoma.
Gu C; Teng X; Sun X; Liu J; Zhu Z; Zhang L; Wu Z; Zou R; Pang J; Lyu X
BMC Cancer; 2024 May; 24(1):585. PubMed ID: 38741038
[TBL] [Abstract][Full Text] [Related]
17. Association between pathologic response and survival after neoadjuvant therapy in lung cancer.
Deutsch JS; Cimino-Mathews A; Thompson E; Provencio M; Forde PM; Spicer J; Girard N; Wang D; Anders RA; Gabrielson E; Illei P; Jedrych J; Danilova L; Sunshine J; Kerr KM; Tran M; Bushong J; Cai J; Devas V; Neely J; Balli D; Cottrell TR; Baras AS; Taube JM
Nat Med; 2024 Jan; 30(1):218-228. PubMed ID: 37903504
[TBL] [Abstract][Full Text] [Related]
18. Pathological nodal disease defines survival outcomes in patients with lung cancer with tumour major pathological response following neoadjuvant chemotherapy.
Corsini EM; Weissferdt A; Pataer A; Zhou N; Antonoff MB; Hofstetter WL; Mehran RJ; Rajaram R; Rice DC; Roth JA; Vaporciyan AA; Walsh GL; Cascone T; Heymach JV; Swisher SG; Sepesi B
Eur J Cardiothorac Surg; 2021 Jan; 59(1):100-108. PubMed ID: 32864702
[TBL] [Abstract][Full Text] [Related]
19. Dynamic alteration in SULmax predicts early pathological tumor response and short-term prognosis in non-small cell lung cancer treated with neoadjuvant immunochemotherapy.
Sun T; Huang S; Jiang Y; Yuan H; Wu J; Liu C; Zhang X; Tang Y; Ben X; Tang J; Zhou H; Zhang D; Xie L; Chen G; Zhao Y; Wang S; Xu H; Qiao G
Front Bioeng Biotechnol; 2022; 10():1010672. PubMed ID: 36277407
[No Abstract] [Full Text] [Related]
20. Appraisal of a revised lymph node classification system for esophageal squamous cell cancer.
Dhar DK; Hattori S; Tonomoto Y; Shimoda T; Kato H; Tachibana M; Matsuura K; Mitsumoto Y; Little AG; Nagasue N
Ann Thorac Surg; 2007 Apr; 83(4):1265-72. PubMed ID: 17383324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]